Pharmaceutical composition containing xylomezoline
By applying xylometazoline nasal spray, its vasoconstrictive and immunomodulatory effects have resolved insomnia and fatigue caused by upper respiratory tract infections, significantly improving patients' sleep quality and energy levels, alleviating symptoms, and significantly enhancing their quality of life.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- HELION CONSUMER HEALTHCARE CO LTD
- Filing Date
- 2024-10-29
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies have failed to effectively address insomnia, sleep disorders, and fatigue caused by upper respiratory tract infections such as the common cold, and these symptoms affect patients' quality of life.
Using a nasal spray containing xylometazoline, administered intranasally up to three times daily, especially at night, utilizes xylometazoline's vasoconstrictive and immunomodulatory effects to improve nasal mucosal inflammation, reduce nitric oxide production, and thus improve sleep quality and energy levels.
It significantly improved sleep quality and energy levels in patients with upper respiratory tract infections, significantly reduced symptoms such as nasal congestion and cough, significantly improved quality of life, and lasted for up to 12 hours.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3